Kathleen D. Scott Sells 12,500 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott sold 12,500 shares of the firm’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $16.00, for a total transaction of $200,000.00. Following the completion of the transaction, the chief financial officer now directly owns 4,949 shares in the company, valued at approximately $79,184. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

ARS Pharmaceuticals Price Performance

ARS Pharmaceuticals stock traded down $0.39 during midday trading on Thursday, hitting $16.13. 963,408 shares of the stock were exchanged, compared to its average volume of 764,199. ARS Pharmaceuticals, Inc. has a 1 year low of $3.35 and a 1 year high of $16.89. The firm has a market cap of $1.56 billion, a P/E ratio of -31.02 and a beta of 0.91. The company has a 50 day moving average price of $13.38 and a two-hundred day moving average price of $10.72.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $2.00 million. As a group, analysts predict that ARS Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new position in ARS Pharmaceuticals during the 3rd quarter worth $30,000. Creative Planning grew its holdings in ARS Pharmaceuticals by 7.0% during the 3rd quarter. Creative Planning now owns 35,263 shares of the company’s stock worth $511,000 after acquiring an additional 2,307 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in ARS Pharmaceuticals during the 2nd quarter worth $180,000. Renaissance Technologies LLC grew its holdings in ARS Pharmaceuticals by 884.9% during the 2nd quarter. Renaissance Technologies LLC now owns 124,100 shares of the company’s stock worth $1,056,000 after acquiring an additional 111,500 shares in the last quarter. Finally, J.W. Cole Advisors Inc. grew its holdings in ARS Pharmaceuticals by 10.8% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after acquiring an additional 1,500 shares in the last quarter. 68.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SPRY has been the topic of a number of research reports. Raymond James raised shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $18.00 to $22.00 in a research note on Tuesday, August 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. William Blair raised shares of ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Leerink Partners raised their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research note on Friday, September 20th. Four analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $24.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.